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We would like to take this opportunity to respond to the recent publication from Barker et al., 
comparing physical activity (PA) of those with and without chronic disease from the UK Biobank 
participants. 1 We commend the authors for raising awareness of the issues associated with low 
levels of PA in patients with chronic disease, and highlight the importance for clinicians to pay more 
attention to PA levels of those with chronic disease, and encourage adequate PA to accrue the 
associated health benefits. The authors conclude that those with chronic disease have lower PA 
levels than their healthy peers. Figure 1 shows that cardiovascular disease participants had the 
second lowest number of minutes per week of moderate activity. Figure 2 in the paper shows that 
people with heart failure have one of the lowest levels of PA of all the chronic diseases, 44% lower 
than healthy counterparts. However, we would like to draw attention to a fundamental limitation of 
this study. 
The accelerometer cut points the authors have used to classify activity into moderate (100mg) or 
vigorous (400mg) intensity have been applied to all participants, both with and without chronic 
disease. These cut points are derived from a small study of 30 healthy adults 2, and have been used 
in a number of studies including those of older adults and patients with heart failure.3-4 The issue lies 
in applying the same intensity thresholds to all participants, as this assumes that energy expenditure 
is the same for all i.e. an activity that generates a vector magnitude between 100-400mg requires 3-
6 METs for everyone, and does not take into account an individual’s exercise capacity. 
Within the discussion the authors hypothesise that in some cases, the disease may be directly 
responsible for lower PA due to reduced exercise capacity, where limitations to cardiopulmonary 
function or musculoskeletal dysfunction occur secondary to the disease. In fact, in this subset of 
participants, it is likely that energy expenditure will not be the same as their healthy peers, because 
of the aforementioned reasons, and often require more energy to complete a given activity.5-6 
Therefore, application of cut points developed in younger, healthier populations to older people or 
those with chronic disease affecting exercise capacity risks researchers underestimating time spent 
in MVPA.  
The authors perform sensitivity analysis to account for this by allowing ±25mg change in the 
thresholds for moderate and vigorous intensity PA, and conclude that this changed the absolute 
minutes per week of activity, but differences between healthy and diseased subgroups remained. 
However, we have conducted an accelerometer calibration study in heart failure patients, which is 
currently in preparation for publication, and have derived acceleration values that relate to 
moderate intensity activity in patients with heart failure. The value of 100mg used in the paper by 
Barker et al. is more than double the value that we observed, which strongly implies the amount of 
MVPA undertaken by this population is underestimated, and PA intensity is being misclassified.  
We do not dispute that PA levels of those with chronic disease are lower than those of their healthy 
counterparts however, we believe the magnitude of the difference between these two groups may 
be exaggerated with the application of the same intensity thresholds. The exaggeration may be two 
fold, where applying an accelerometer threshold of 100mg may be too low for healthy participants 
and therefore overestimating the amount of MVPA, and too high for those with chronic disease, 
therefore underestimating the amount of MVPA.  
With National PA recommendations still based on the amount of time spent in MVPA, and with the 
increasing use of accelerometers in population health research, it is vital that accelerometer data is 
interpreted correctly, particularly in people with chronic disease. If a threshold that is too high is 
used to classify accelerometer data and for clinicians to make PA recommendations that may be too 
difficult for these participants to perform, they will become demoralised, demotivated and less likely 
to make the behaviour change that is so important for their health.7 
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